Pharmaceuticals News and Research

RSS

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.

23 Jan 2014

ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.

23 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Compact liquid handling workstation for PCR launched by Hamilton Robotics

At the annual Society for Laboratory Automation and Screening (SLAS) conference, Hamilton Robotics has introduces the NIMBUS® PCR Workstation, which is a compact and affordable pipetting workstation enabling fast and flexible assay setup for endpoint, real-time, qPCR or multiplex PCR.

23 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

Rice University scientists have created a way to fine tune a process critical to the pharmaceutical industry that could save a lot of time and money.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.

23 Jan 2014

Scientists give cautious welcome for new types of drug intended for use in place of antibiotics

New types of drug intended for use in place of antibiotics have been given a cautious welcome by scientists.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Study provides new information about life expectancy of people with multiple sclerosis

The first large scale study in the U.S. on the mortality of patients with multiple sclerosis has been published and provides new information about the life expectancy of people with the disease. The study appears in the journal Multiple Sclerosis and Related Disorders.

21 Jan 2014

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.

21 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Par Pharmaceutical Companies, Inc. today announced that it has entered into a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals, a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products.

21 Jan 2014

Synthelis secures initial funding to accelerate commercial development of membrane proteins

Synthelis, a company specializing in the production and characterization of therapeutic targets and antigens, announces today that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.

21 Jan 2014

New Microlab® NIMBUS® Select workstation with Ranger Technology launched by Hamilton Robotics and Coastal Genomics

At the annual Society for Laboratory Automation and Screening (SLAS) meeting Hamilton Robotics has announced a partnership with Coastal Genomics to launch the new Microlab® NIMBUS® Select workstation with Ranger Technology. The new automated workstation provides a faster and more economical automated solution to agarose gel selection of DNA fragments, generating high-quality material for downstream use in next-generation sequencing (NGS), cloning and gene synthesis applications.

20 Jan 2014

Pharmaceuticals News and Research

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

Compact liquid handling workstation for PCR launched by Hamilton Robotics

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists give cautious welcome for new types of drug intended for use in place of antibiotics

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Study provides new information about life expectancy of people with multiple sclerosis

Kolltan Pharmaceuticals announces treatment of first cancer patient with KTN3379

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Synthelis secures initial funding to accelerate commercial development of membrane proteins

New Microlab® NIMBUS® Select workstation with Ranger Technology launched by Hamilton Robotics and Coastal Genomics

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence